ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.

Kelly J Norsworthy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.